Mereo BioPharma Group plc (MREO) stock
MREONasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.29+0.01 (+5.39%)
Close on Nov 18, 2026Market cap $46.20MP/E –Yield –
Mereo BioPharma r&d expenses
Research and development expenses are spending on new products and technology.
Mereo BioPharma's R&D Expenses for the twelve months ending Sep 30, 2026 was $12.84M, down 42.7% year over year. For fiscal 2025 it was $17.77M, down 15.1% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.77M | -15.1% |
| FY2024 | Dec 31, 2024 | $20.93M | +20.2% |
| FY2023 | Dec 31, 2023 | $17.42M | -40.9% |
| FY2022 | Dec 31, 2022 | $29.47M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $2.09M | -51.1% |
| Q2 FY2026 | Jun 30, 2026 | $1.81M | -66.4% |
| Q1 FY2026 | Mar 31, 2026 | $4.75M | +20.8% |
| Q4 FY2025 | Dec 31, 2025 | $4.19M | -52.5% |
| Q3 FY2025 | Sep 30, 2025 | $4.27M | +34.7% |
| Q2 FY2025 | Jun 30, 2025 | $5.37M | +8.6% |
| Q1 FY2025 | Mar 31, 2025 | $3.93M | -1.6% |
| Q4 FY2024 | Dec 31, 2024 | $8.82M | +83.6% |
| Q3 FY2024 | Sep 30, 2024 | $3.17M | -11.8% |
| Q2 FY2024 | Jun 30, 2024 | $4.95M | +33.2% |
| Q1 FY2024 | Mar 31, 2024 | $3.99M | -24.7% |
| Q4 FY2023 | Dec 31, 2023 | $4.80M | – |
| Q3 FY2023 | Sep 30, 2023 | $3.59M | – |
| Q2 FY2023 | Jun 30, 2023 | $3.71M | – |
| Q1 FY2023 | Mar 31, 2023 | $5.31M | – |
See a number that looks wrong?